• Perifosine: Akt Signaling as a Causal Assay Probe

  2026-08-16

  Perifosine (KRX-0401) is examined here as more than an apoptosis reagent: it is a mechanistic perturbation tool for testing Akt-linked stress responses. The article connects oncology evidence with the PEDF–PI3K/Akt/mTOR framework reported in cerebral ischemia/reperfusion research while defining the limits of that cross-domain interpretation.

• Plk1 Control of p31comet in Mitotic Checkpoint Exit

  2026-08-15

  The reference study identifies Polo-like kinase 1 (Plk1) as a negative regulator of p31comet-dependent mitotic checkpoint complex disassembly. By combining HeLa cell extracts, purified proteins, phosphosite analysis, and an S102A mutant, the authors show how Plk1 phosphorylation can prevent premature checkpoint inactivation and reduce futile MCC cycling.

• CUX2 Neuron Loss and DNA Damage in Neuroinflammation

  2026-08-14

  The reference study identifies DNA damage burden and inadequate double-strand break repair as drivers of selective CUX2-positive layer 2/3 excitatory neuron loss during neuroinflammation. Its combination of human multiple sclerosis tissue, mouse inflammatory models, genetic perturbation, and interferon-γ experiments links neuronal vulnerability to a defined stress-response and repair axis.

• Cell Cycle Assay Kit for CRC Response Profiling

  2026-08-14

  Use PI-based DNA-content profiling to connect colorectal cancer treatment responses with G0/G1, S, and G2/M redistribution. This workflow pairs the Cell Cycle Assay Kit with apoptosis readouts and metabolic studies to clarify how CGF-associated stress affects proliferation without overstating what DNA content alone can prove.

• Mianserin HCl: Findings from a Controlled Trial

  2026-08-13

  The reference paper evaluated mianserin hydrochloride against amitriptyline using blinded clinical ratings, systematic side-effect monitoring, and serial plasma drug measurements. It found broadly similar antidepressant efficacy, fewer recorded adverse effects with mianserin, and no clear relationship between plasma mianserin concentration and therapeutic response.

• Fludarabine Workflow for DNA Synthesis Studies

  2026-08-13

  Build a reproducible Fludarabine workflow that connects DNA replication stress with cell-cycle arrest and apoptosis readouts. Practical dosing, solubility control, genotype-aware design, and troubleshooting make it useful for leukemia research, multiple myeloma research, and translational assay development.

• MSNs@SF-HA-FA Targets NSCLC Metastasis

  2026-08-12

  Li et al. identify an SPI1/miR-616-5p regulatory axis that promotes non-small cell lung cancer invasion and migration, and show that sulforaphane can inhibit this pathway. A hyaluronic acid- and folic acid-modified mesoporous silica nanoparticle system improves sulforaphane stability, uptake, tumor targeting, and anti-metastatic activity in NSCLC xenograft models.

• Gramine: From Target Engagement to Ferroptosis

  2026-08-12

  Gramine is a mechanism-rich ferroptosis inducer for cancer biology research, with particular relevance to triple-negative breast cancer. This article explains how to distinguish CUL3–MTDH target engagement from downstream cell-death phenotypes and design more defensible assays.

• Chemotherapy Enhances Neoantigen-Directed T Cell Therapy

  2026-08-11

  Sagie et al. identify the KRAS.G12V-specific TCR T104 and show that lymphodepleting chemotherapy improves neoantigen-directed killing by increasing immunoproteasome activity, HLA-I expression, and peptide presentation. The study provides a mechanistic framework for optimizing chemotherapy before TCR-T cells, tumor-infiltrating lymphocytes, or T cell engagers, while emphasizing that the evidence remains preclinical.

• Firefly Luciferase mRNA: Workflow & Optimization

  2026-08-11

  Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP) provides a sensitive, non-destructive readout for transfection benchmarking, gene expression assays, cell viability assays, and delivery studies. Its capped, modified architecture helps researchers distinguish payload performance from formulation or handling failures.

• Intravesical p21 mRNA–LNP Therapy in Bladder Cancer

  2026-08-10

  The reference study develops chemically modified p21 mRNA encapsulated in lipid nanoparticles for localized intravesical treatment of bladder cancer. Its experiments connect bladder-restricted protein expression with tumor suppression in an orthotopic mouse model, while also defining important mechanistic and translational limitations for mRNA-based tumor suppressor replacement.

• Dextrose in Hypoxic Tumor Models

  2026-08-09

  Dextrose (D-glucose) is more than a routine carbon source in glucose metabolism research. This article shows how to use it as a defined experimental variable for modeling nutrient competition, hypoxia, and immune dysfunction in tumor microenvironments.

• Capecitabine in Tumor–Stroma Precision Testing

  2026-08-08

  Capecitabine is more than a 5-fluorouracil prodrug: it is a mechanistically informative probe for studying activation biology, tumor–stroma interactions, and response heterogeneity. By combining its thymidine phosphorylase-linked activation with patient-derived gastric cancer assembloids, translational researchers can build more discriminating preclinical oncology research workflows while avoiding overinterpretation of tumor-only assays.

• Benzyl-activated Streptavidin Magnetic Beads: Assay Design

  2026-08-07

  Discover how Benzyl-activated Streptavidin Magnetic Beads support selective biotinylated molecule capture, from immunoprecipitation to mechanistically informed cell-death workflows. This guide connects annexin-V biology with practical magnetic separation while clearly distinguishing validated evidence from experimental adaptation.

• Technical Guide: EdU Flow Cytometry Assay Kits (Cy5) for S-P

  2026-08-07

  The EdU Flow Cytometry Assay Kits (Cy5) enable robust detection of S-phase DNA synthesis in proliferating cells using copper-catalyzed azide-alkyne cycloaddition (CuAAC) click chemistry. This kit is best suited for flow cytometry–based cell proliferation assays where denaturation-free workflow, multiplexing, and high sensitivity are required. Applications beyond flow cytometry or fixed tissue analysis are not validated.

15992 records 1/1067 page Next 12345 下5页 Last page